Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $91.20 Consensus PT from Analysts

by · The Markets Daily

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has earned an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $91.20.

A number of equities research analysts recently weighed in on HALO shares. Citizens Jmp upped their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. UBS Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st.

Check Out Our Latest Stock Report on HALO

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $110.19 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a market cap of $12.51 billion, a price-to-earnings ratio of 32.89, a price-to-earnings-growth ratio of 0.43 and a beta of 0.88. The stock’s 50-day moving average is $91.42 and its two-hundred day moving average is $76.00. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the business earned $1.54 EPS. Halozyme Therapeutics’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts forecast that Halozyme Therapeutics will post 7.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 32,478 shares of company stock valued at $3,076,604. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its holdings in shares of Halozyme Therapeutics by 7,724.2% during the 2nd quarter. California State Teachers Retirement System now owns 10,668,044 shares of the biopharmaceutical company’s stock worth $834,988,000 after buying an additional 10,531,698 shares during the last quarter. Bank of America Corp DE acquired a new position in Halozyme Therapeutics in the second quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $196,540,000. Norges Bank acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $128,201,000. Finally, Jupiter Topco LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $105,570,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Featured Stories